Skip to Content

Cantel Medical Corp.

Merger

  • Date:
  • 1/12/2021
  • Company Name:
  • Cantel Medical Corp.
  • Stock Symbol:
  • CMD
  • Company Name - Buyer:
  • STERIS plc
  • Stock Symbol - Buyer:
  • STE
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 1/12/2021

Case Finder

Locate any case using the tools below.

NEW YORK, January 12, 2020 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Cantel Medical Corp. (NYSE: CMD) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by STERIS plc (NYSE: STE).

On January 12, 2021, Cantel announced that it had signed an agreement to be acquired by STERIS for approximately $4.6 billion.  Pursuant to the merger agreement, Cantel stockholders will receive $16.93 in cash and 0.33787 shares of STERIS common stock for each share of Cantel common stock owned.  The deal is scheduled to close by the end of STERIS’s first quarter of fiscal 2022 (ending June 30, 2021).

Bragar Eagel & Squire is concerned that Cantel’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Cantel’s stockholders.
 
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Cantel Medical Corp.. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: